<DOC>
	<DOCNO>NCT02511132</DOCNO>
	<brief_summary>This multicenter , 1:1 randomized Phase IIb study intradermal autologous Vigil™ cancer vaccine patient metastatic Ewing 's sarcoma Family Tumors ( ESFT ) refractory intolerant least 2 prior line chemotherapy . Patients undergo standard surgical procedure ( e.g. , tumor biopsy palliative resection ) may tumor tissue harvest manufacture investigational product . Patients meet eligibility criterion randomize receive either ( 1 ) intradermal Vigil every 28 day 4-12 administration , ( 2 ) gemcitabine 675 mg/m2 IV 10 mg/m2/min D1 D8 docetaxel 75 mg/m2 IV D8 every 21 day . The primary trial objective determine overall survival patient treat Vigil™ versus gemcitabine/docetaxel .</brief_summary>
	<brief_title>Randomized Phase IIb Trial Vigil Versus Gemcitabine + Docetaxel Ewing 's Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Tissue Procurement Patients eligible tissue procurement Vigil™ manufacturing process , meet follow criterion : 1 . Histologically confirm Ewing 's Sarcoma Family Tumors ( ESFT ) . 2 . Age ≥2 year . 3 . Estimated survival ≥ 6 month . 4 . Evidence EWS translocation FISH RTPCR . 5 . Metastatic disease 6 . Refractory intolerant ≥ 2 line systemic chemotherapy . 7 . Planned standard care surgical procedure ( e.g. , tumor biopsy palliative resection thoracentesis ) expect availability cumulative mass ~1030 gram tissue ( `` golfball '' size ) pleural fluid estimate volume ≥ 500mL ( must primary tap ) immunotherapy manufacture . 8 . Tumor intend immunotherapy manufacture embed bone contain luminal tissue ( e.g . bowel , ureter , bile duct ) . 9 . Ability understand willingness sign write informed consent document tissue harvest . Tissue Procurement Patients meeting follow criterion eligible tissue procurement Vigil™ manufacturing : 1 . Medical condition require form chronic systemic immunosuppressive therapy ( steroid ) except physiologic replacement dose hydrocortisone equivalent ( 30 mg hydrocortisone 10 mg prednisone equivalent daily ) &lt; 30 day duration . 2 . Known history malignancy unless undergone curative intent therapy without evidence disease ≥ 3 year except cutaneous squamous cell basal cell skin cancer , superficial bladder cancer , situ cervical cancer situ cancer allow definitively resect . 3 . Brain metastasis unless treat curative intent ( gamma knife surgical resection ) without evidence progression ≥ 2 month . 4 . Any documented history autoimmune disease exception Type 1 diabetes stable insulin regimen , hypothyroidism stable dose replacement thyroid medication , vitiligo , asthma require systemic steroid . 5 . Known history allergy sensitivities gentamicin . 6 . Known hypersensitivity reaction docetaxel drug formulate polysorbate 80 would preclude treatment docetaxel . 7 . History current evidence condition ( include medical , psychiatric substance abuse disorder ) , therapy , laboratory abnormality might confound result study , interfere patient 's participation full duration study , best interest patient participate , opinion treat Investigator . 8 . Known HIV chronic Hepatitis B C infection . Study Enrollment Patients eligible registration randomization meet follow inclusion criterion : 1 . Successful manufacturing least 4 vial Vigil™ . 2 . Karnofsky performance status ( PS ) ≥60 % . 3 . Estimated survival ≥ 4 month . 4 . Normal organ marrow function define : Absolute granulocyte count ≥1,500/mm3 Absolute lymphocyte count ≥400/mm3 Platelets ≥100,000/mm3 Total bilirubin ≤ institutional upper limit normal AST ( SGOT ) /ALT ( SGPT ) ≤2x institutional upper limit normal Creatinine &lt; 1.5 mg/dL 5 . Subject recover CTCAE Grade 1 good adverse event associate prior therapy surgery . Preexisting motor sensory neurologic pathology symptom must recover CTCAE Grade &gt; 2 better . 6 . If female childbearing potential , negative urine serum pregnancy test . If urine test positive confirm negative , negative serum test require study entry . 7 . Ability understand willingness sign write inform protocol specific consent . Study Enrollment Measureable disease requirement enrollment onto trial . In addition procurement exclusion criterion , patient NOT eligible study registration randomization meeting follow criterion : 1 . Any antineoplastic therapy tissue procurement vaccine manufacture start study therapy . 2 . Live vaccine use prevention infectious disease administer &lt; 30 day prior start study therapy . 3 . Postsurgery complication opinion treat investigator would interfere patient 's study participation make best interest patient participate .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ewing 's Sarcoma Family Tumors , ESFT , Sarcoma</keyword>
</DOC>